

12 Feb 2023 | News

Quick Listen: Scrip's Five Must-Know Things

by [Ian Haydock](#)

In this week's podcast version of Five Must-Know Things: Merck remains confident in TIGIT; Otezla and Sotyktu battle for share in psoriasis; GSK chief warns about worsening UK pharma sector; China plans to ban gene editing technology exports; and an interview with Boehringer Ingelheim's head of human pharma regions.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 10 February 2023, including: [Merck & Co., Inc.](#) remains confident in TIGIT; Otezla and Sotyktu battle for share in psoriasis; [GSK plc](#) chief warns about worsening UK pharma sector; China plans to ban gene editing technology exports; and an interview with [Boehringer Ingelheim GmbH](#)'s head of human pharma regions.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Merck & Co. Remains 'Very Confident' In TIGIT](#)" - Scrip, 2 Feb, 2023.)

(Also see "[Amgen's Otezla And BMS's Sotyktu Battle For Share In Oral Psoriasis Drug Market](#)" - Scrip, 6 Feb, 2023.)

(Also see "[Worsening UK Pharma Sector Close To 'Tipping Point,' Warns GSK Chief](#)" - Scrip, 6 Feb, 2023.)

(Also see "[*China Planning To Ban Gene Editing Technology Exports*](#)" - Scrip, 6 Feb, 2023.)

(Also see "[*Profile: Boehringer's Andersen On Volleyball And Leadership Learnings, Storytelling*](#)" - Scrip, 3 Feb, 2023.)

[Click here to explore this interactive content online](#) ✨